Caseware UK (AP4) 2021.0.152 2021.0.152 2021-12-312021-12-311true1true2021-01-01No description of principal activitytrue 11077480 2021-01-01 2021-12-31 11077480 2020-01-01 2020-12-31 11077480 2021-12-31 11077480 2020-12-31 11077480 c:Director1 2021-01-01 2021-12-31 11077480 c:RegisteredOffice 2021-01-01 2021-12-31 11077480 d:OfficeEquipment 2021-01-01 2021-12-31 11077480 d:ComputerEquipment 2021-01-01 2021-12-31 11077480 d:CurrentFinancialInstruments 2021-12-31 11077480 d:CurrentFinancialInstruments 2020-12-31 11077480 d:CurrentFinancialInstruments d:WithinOneYear 2021-12-31 11077480 d:CurrentFinancialInstruments d:WithinOneYear 2020-12-31 11077480 d:ShareCapital 2021-12-31 11077480 d:ShareCapital 2020-12-31 11077480 d:RetainedEarningsAccumulatedLosses 2021-12-31 11077480 d:RetainedEarningsAccumulatedLosses 2020-12-31 11077480 c:EntityNoLongerTradingButTradedInPast 2021-01-01 2021-12-31 11077480 c:FRS102 2021-01-01 2021-12-31 11077480 c:AuditExempt-NoAccountantsReport 2021-01-01 2021-12-31 11077480 c:FullAccounts 2021-01-01 2021-12-31 11077480 c:PrivateLimitedCompanyLtd 2021-01-01 2021-12-31 iso4217:GBP xbrli:pure
Company registration number: 11077480







UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2021


G MEDICAL INNOVATIONS UK LIMITED






































img1ce4.png                        

 


G MEDICAL INNOVATIONS UK LIMITED
 


 
COMPANY INFORMATION


Director
Mr Y Geva 




Registered number
11077480



Registered office
3000a Parkway
Whiteley

Hampshire

PO15 7FX




Accountants
Menzies LLP
Chartered Accountants

3000a Parkway

Whiteley

Hampshire

PO15 7FX





 


G MEDICAL INNOVATIONS UK LIMITED
 



CONTENTS



Page
Statement of financial position
1
Notes to the financial statements
2 - 3


 


G MEDICAL INNOVATIONS UK LIMITED
REGISTERED NUMBER:11077480



STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2021

2021
2020
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 3 
23,117
31,320

  
23,117
31,320

Creditors: amounts falling due within one year
 4 
(156,220)
(164,423)

Net current liabilities
  
 
 
(133,103)
 
 
(133,103)

Total assets less current liabilities
  
(133,103)
(133,103)

  

Net liabilities
  
(133,103)
(133,103)


Capital and reserves
  

Called up share capital 
  
10
10

Profit and loss account
  
(133,113)
(133,113)

  
(133,103)
(133,103)


For the year ended 31 December 2021 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr Y Geva
Director

Date: 7 September 2022

The notes on pages 2 to 3 form part of these financial statements.

Page 1

 


G MEDICAL INNOVATIONS UK LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

1.


General information

G Medical Innovations UK Limited is a private company limited by shares, registered in England and Wales. The address of its registered office is disclosed on the company information page.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

As explained in note 2.2, the company transferred its trade to its parent company on 1 January 2021 and has ceased trading. As required by UK accounting standards, the director has prepared the financial statements on the basis that the company is no longer a going concern. No material adjustments arose as a result of ceasing to apply the going concern basis.

 
2.2

Going concern

During the reporting period, the trade of G Medical Innovations UK Limited was incorporated into its parent company G Medical Innovations Holdings Limited.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 2

 


G MEDICAL INNOVATIONS UK LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

2.Accounting policies (continued)


2.4
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
25%
Computer equipment
-
25%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.


3.


Debtors

2021
2020
£
£


Amounts owed by group undertakings
23,117
23,117

Other debtors
-
8,203

23,117
31,320



4.


Creditors: Amounts falling due within one year

2021
2020
£
£

Trade creditors
-
6,161

Amounts owed to group undertakings
156,220
152,262

Accruals and deferred income
-
6,000

156,220
164,423


 
Page 3